$0.83
0.36% today
Nasdaq, Jul 31, 04:12 pm CET
ISIN
US31447E1055
Symbol
FEMY

Femasys Inc Stock price

$0.83
-0.14 14.06% 1M
-0.36 30.25% 6M
-0.27 24.55% YTD
-0.29 25.89% 1Y
-0.98 54.14% 3Y
-11.17 93.08% 5Y
-11.17 93.08% 10Y
-11.17 93.08% 20Y
Nasdaq, Closing price Wed, Jul 30 2025
-0.01 0.98%

Key metrics

Basic
Market capitalization
$27.0m
Enterprise Value
$28.9m
Net debt
$1.9m
Cash
$3.8m
Shares outstanding
27.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
15.9 | 4.4
EV/Sales
17.0 | 4.7
EV/FCF
negative
P/B
13.5
Financial Health
Equity Ratio
18.5%
Return on Equity
-816.6%
ROCE
-575.1%
ROIC
-280.3%
Debt/Equity
2.9
Financials (TTM | estimate)
Revenue
$1.7m | $6.3m
EBITDA
$-19.5m | -
EBIT
$-19.8m | $-20.3m
Net Income
$-21.1m | $-17.6m
Free Cash Flow
$-20.5m
Growth (TTM | estimate)
Revenue
61.9% | 283.6%
EBITDA
-34.1% | -
EBIT
-32.5% | -14.1%
Net Income
-41.7% | 6.8%
Free Cash Flow
-52.8%
Margin (TTM | estimate)
Gross
66.2%
EBITDA
-1,146.0% | -
EBIT
-1,164.3%
Net
-1,242.6% | -280.6%
Free Cash Flow
-1,206.2%
More
EPS
$-0.8
FCF per Share
$-0.8
Short interest
0.6%
Employees
33
Rev per Employee
$50.0k
Show more

Is Femasys Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,020 stocks worldwide.

Femasys Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Femasys Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Femasys Inc forecast:

Buy
90%
Hold
10%

Financial data from Femasys Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1.70 1.70
62% 62%
100%
- Direct Costs 0.57 0.57
58% 58%
34%
1.13 1.13
64% 64%
66%
- Selling and Administrative Expenses 11 11
44% 44%
658%
- Research and Development Expense 9.41 9.41
26% 26%
554%
-19 -19
34% 34%
-1,145%
- Depreciation and Amortization 0.31 0.31
26% 26%
18%
EBIT (Operating Income) EBIT -20 -20
32% 32%
-1,164%
Net Profit -21 -21
42% 42%
-1,242%

In millions USD.

Don't miss a Thing! We will send you all news about Femasys Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Femasys Inc Stock News

Neutral
GlobeNewsWire
about one month ago
-- Milestone expands global reach and reinforces commitment to accessible, first-line infertility solutions -- ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products announces the achieve...
Neutral
GlobeNewsWire
about one month ago
ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces Conformité Européene (CE) mark certification under European Union Medical Device Regulation (EU MDR 2017/745) of the Class...
Neutral
GlobeNewsWire
about one month ago
--New CCO to Lead U.S. Commercialization of Fertility Products, Including FemaSeed ® , and Expand Strategic Global Partnerships Across Full Portfolio-- ATLANTA, June 17, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc. (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and d...
More Femasys Inc News

Company Profile

Femasys, Inc. operates as a medical device company that focuses on women's healthcare. Its products include FemVue Saline-Air Device, which creates and delivers an alternating pattern of saline and air as a continuous stream, and enables physicians to assess their patients fallopian tubes, and FemChec Pressure Management Device, which limits the maximum applied pressure while performing hysterosalpingogram. The firm offers FemCerv, an endocervical curettage device to collect a non-contaminated tissue sample for cervical cancer screening. The company was founded by Kathy Lee-Sepsick in 2004 and is headquartered in Suwanee, GA.

Head office United States
CEO Kathy Lee-Sepsick
Employees 33
Founded 2004
Website www.femasys.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today